CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
Quetzal Therapeutics
Orca Biosystems, Inc.
Genmab
AbbVie
Janssen Research & Development, LLC
Actuate Therapeutics Inc.
Celgene
Pfizer
Inmune Bio, Inc.
AbbVie
Rigel Pharmaceuticals
Cellectar Biosciences, Inc.
Takeda
Vanda Pharmaceuticals
Astellas Pharma Inc
AbbVie
AbbVie
Nanjing RegeneCore Biotech Co., Ltd.
AbbVie
First Ascent Biomedical Inc.
AbbVie
AbbVie
AbbVie
AbbVie
AbbVie
Massive Bio, Inc.
Constellation Pharmaceuticals
AbbVie
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
AbbVie
AbbVie
Biomea Fusion Inc.
AbbVie
Century Therapeutics, Inc.
Cogent Biosciences, Inc.
Tempus AI
AbbVie
AbbVie
Servier
Genmab
Hikma Pharmaceuticals LLC
Daiichi Sankyo
Adaptimmune
AbbVie
Janssen Research & Development, LLC
Zhejiang DTRM Biopharma
Taproot Health
Celularity Incorporated
CytoMed Therapeutics Pte Ltd